On the other hand, selective BRAF inhibitors (BRAFi) have demonstrated remarkable clinical activity in melanoma patients carrying BRAFV600 mutations [9], which improved with the combination with MEK inhibitors (MEKi). Here, BRAF is linked to melanoma.